Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEEp Sea phase 3 study of LP352 in Dravet syndrome
jRCT2011250046Phase 3Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Dravet syndrome comparing LP352 with Placebo (2 arms). Primary endpoint: Frequency percent change in countable motor seizures during treatment compared with baseline. Started Oct 2025; status: active, not recruiting.
02
Drugs
bexicaserin
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on jRCT2011250046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250046.